BioSpace News Archive

Guests gathered to raise funds for stomach cancer research and honor the legacy of late DDF Founder Debbie Zelman

The bike features a chest pad that allows users to rest their upper body during cycling while the locking mechanism transforms this unique bike into a regular road bike.

According to data compiled by Hemp Business Journal, a division of New Frontier Data, the U.S. hemp industry totaled USD 820 Million in sales in 2017 and is projected to grow to USD 1.9 Billion by 2022, growing at a CAGR of 14.4% during the forecasted period.

Just over half of consumers across the EU5 markets reported asking their doctor for a specific medication in the past 12 months – and half of these patients said they were always prescribed the requested drug.

Multiple Studies of DNAtrix Oncolytic Viruses to be Presented at the SNO Annual Meeting

Copyright Clearance Center, Inc. (CCC), a leader in advancing copyright, accelerating knowledge, and powering innovation, announces enhancements to its award-winning content workflow solution, RightFind®, making it even easier to use than ever before, giving scientific research organizations access to content they need – anytime, anywhere.

Company Integrates Latest Acquisition and Builds Corporate Foundation for Growth

Relatient today announced it ranked 190 on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America.

PharmaCyte Biotech (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed a U.S. Food and Drug Administration (FDA) required formal report on the safety studies conducted by Bavarian Nordic

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that data from the dose escalation portion of its Phase 1 trial of SY-1365, its first-in-class selective cyclin-dependent kinase 7 (CDK7) inhibitor, demonstrated proof-of-mechanism at tolerable doses in patients with advanced solid tumors.